CA2062854A1 — Pharmaceutical aerosol formulations
Assigned to Novartis AG · Expires 1992-09-15 · 34y expired
What this patent protects
Pharmaceutical Aerosol Formulations Abstract The present invention relates to an aerosol formulation comprising: a) a liquefied propellant gas or propellant gas mixture from the group of the alternative propellant gases that do not have removable chlorine atoms; b) a non-ionic su…
USPTO Abstract
Pharmaceutical Aerosol Formulations Abstract The present invention relates to an aerosol formulation comprising: a) a liquefied propellant gas or propellant gas mixture from the group of the alternative propellant gases that do not have removable chlorine atoms; b) a non-ionic surfactant from the group of the monoacetylated or diacetylated monoglyc-erides of the MYVACET series; c) a pharmaceutical active ingredient or active ingredient combination and, if necessary, d) other conventional pharmaceutical excipients that are suitable for aerosol formulations. The aerosol formulation can be used especially in inhalation therapy for the treatment of disorders of the upper respiratory tract, such as asthma or rhinitis.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.